Logo Mark
Publications

ASH 2018

All Publications

Imetelstat Treatment Leads to Durable Transfusion Independence in RBC Transfusion-Dependent, Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent Who Are Lenalidomide and HMA Naive

Clinical Imetelstat: MDSImetelstat
ASH 2018

Steemsma D, et al.

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

Clinical Imetelstat: MFImetelstat
ASH 2018

Mascarenhas J, et al.